Virbac Reports 7.9% Organic Growth in 2025
Animal health company Virbac recorded a revenue of 1,465 million euros in 2025, up by 7.9% on a like-for-like and constant exchange rate basis, according to the press release issued this Tuesday.
Financial Performance in 2025
The group achieved a consolidated revenue of 1,465 million euros for the fiscal year 2025, compared to 1,397 million euros the previous year, the company reports. This performance represents an organic growth of 7.9% on a like-for-like and constant exchange rate basis. At actual rates, the increase was 4.8%, affected by unfavorable exchange rate effects. The pet segment grew by 10.9%, the press release specifies. In the fourth quarter, revenue reached 362 million euros, up 7.1% on a like-for-like and constant exchange rate basis compared to the same period in 2024. The acquisition of Sasaeah in Japan in April 2024 contributed 0.8 percentage points to the annual growth, according to the group. Europe, the IMEA region, and the Pacific were the main contributors to the performance in the last quarter.
Recent Acquisition and Product Launch
Virbac has recently acquired Thyronorm, a product for the treatment of feline hyperthyroidism, the press release indicates. This specialty drug generates about 15 million euros in annual revenue and targets a condition that affects more than 10% of older cats, according to the company. The group will handle direct distribution in the United Kingdom, Australia, and New Zealand under the name Thyronorm, and in the United States under the name Felanorm, the document specifies. In Europe, distribution will gradually shift from current partners Boehringer Ingelheim and Elanco to Virbac over the next few years. This operation is expected to be accretive to sales and EBITDA margin from the first year, the group claims.
Outlook for 2026
For the fiscal year 2026, Virbac anticipates that the acquisition of Thyronorm will contribute approximately 1 percentage point to revenue growth and 0.5 point to adjusted operating income, according to the press release. The company has included this operation in its organic scope for 2026 due to its materiality level, in accordance with its reporting standards. The group has also considered in its outlook the impact of U.S. tariffs, which it estimates at about 4 million dollars over a full year. Virbac reports having invested a record level in research and development as well as in its industrial sites during the fiscal year 2025, including the launch of Vikaly, presented as the world's first medicated pet food.
